Skip to main content

Table 1 Demographics and clinical characteristics of CML cohort

From: Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective

  Total CML-CP Patients (n=303)
Gender (n, %)  
 Male 140 (46.2%)
 Female 163 (53.8%)
Age (mean years, SD) 51.5 (±13.6) years
Time since CML diagnosis (mean years, SD) 4.8 (±4.5) years
Time since CML diagnosis (n, %)  
 <2 years 76 (25.1%)
 2 to <5 years 90 (29.7%)
 ≥ 5 years 136 (44.9%)
 Unknown 1 (0.3%)
Country (n, %)  
 USA 152 (50.2%)
 Italy 37 (12.2%)
 Germany 33 (10.9%)
 Spain 32 (10.6%)
 United Kingdom 25 (8.3%)
 France 24 (7.9%)
Time on Current CML Treatment (median years, IQR) 2.75 (4.8)
Current CML Treatment (n, %)  
 Imatinib 208 (68.6%)
 Nilotinib 49 (16.2%)
 Dasatinib 38 (12.5%)
 Other 4 (1.3%)
 Decline to answer 4 (1.3%)
No. of Comorbidities (mean, SD) 1.4 (±2.4)
Comorbidities (n, %)  
 Hypertension 49 (16.2%)
 Insomnia/sleep difficulties 32 (10.6%)
 Depression 25 (8.3%)
 Arthritis 24 (7.9%)
 Anxiety 24 (7.9%)
 Anemia 21 (6.9%)
  1. Note: CML=Chronic Myeloid Leukemia, CP=Chronic Phase, SD=Standard Deviation, IQR=Inter Quartile Range.